SH0:F:F-Shionogi & Co. Ltd (EUR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 12.6

Change

-1.30 (-9.35)%

Market Cap

USD 10.96B

Volume

88.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MRKC:F MERCK KGAA NAM.SP.ADR

-0.60 (-1.95%)

USD 68.55B
MRK:F Merck & Company Inc

-1.65 (-1.08%)

USD 67.36B
RDDA:F Dr. Reddy's Laboratories Limit..

-2.00 (-2.86%)

USD 59.15B
H6D0:F Haleon PLC

-0.08 (-1.84%)

USD 41.60B
TKDA:F Takeda Pharmaceutical Company ..

+0.20 (+1.61%)

USD 41.17B
H6D:F Haleon PLC

-0.10 (-1.12%)

USD 40.82B
TEV:F Teva Pharmaceutical Industries..

+0.20 (+1.18%)

USD 19.32B
3KY:F HANSOH PHARMAC. HD-00001

-0.26 (-11.11%)

USD 15.54B
NB3:F Neurocrine Biosciences Inc

+0.80 (+0.75%)

USD 10.71B
0C8:F Catalent Inc

-0.18 (-0.33%)

USD 9.81B

ETFs Containing SH0:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -70.56% 10% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -70.56% 10% F 6% D-
Trailing 12 Months  
Capital Gain -70.97% 11% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -70.97% 11% F 7% C-
Trailing 5 Years  
Capital Gain -75.82% 23% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -75.82% 23% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain -3.89% 54% F 33% F
Dividend Return 145.39% 96% N/A 96% N/A
Total Return 149.27% 92% A 93% A
Risk Return Profile  
Volatility (Standard Deviation) 131.23% 8% B- 8% B-
Risk Adjusted Return 110.79% 98% N/A 97% N/A
Market Capitalization 10.96B 96% N/A 86% B+

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector